BioCentury
ARTICLE | Clinical News

MG01CI from Alcobra, Teva meets ADHD endpoint

September 8, 2011 1:33 AM UTC

Alcobra Ltd. (Tel Aviv, Israel) and Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) said MG01CI met the primary endpoint vs. placebo in a Phase II trial to treat adult ADHD. The extended-release formulation of metadoxine significantly improved Conners' Adult ADHD Rating Scale-Investigator Rated Total ADHD Symptoms scores (CAARS-INV) at week six vs. placebo (p<0.03). The trial enrolled 120 patients. ...